KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Profit After Tax (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Profit After Tax for 13 consecutive years, with -$105.3 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 60.25% to -$105.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$345.9 million through Dec 2025, down 47.62% year-over-year, with the annual reading at -$345.9 million for FY2025, 47.62% down from the prior year.
  • Profit After Tax for Q4 2025 was -$105.3 million at Xenon Pharmaceuticals, down from -$90.9 million in the prior quarter.
  • The five-year high for Profit After Tax was -$15.4 million in Q3 2021, with the low at -$105.3 million in Q4 2025.
  • Average Profit After Tax over 5 years is -$48.3 million, with a median of -$46.1 million recorded in 2023.
  • The sharpest move saw Profit After Tax crashed 12533.71% in 2021, then fell 14.87% in 2024.
  • Over 5 years, Profit After Tax stood at -$25.6 million in 2021, then crashed by 46.28% to -$37.4 million in 2022, then fell by 19.65% to -$44.7 million in 2023, then tumbled by 46.81% to -$65.7 million in 2024, then plummeted by 60.25% to -$105.3 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$105.3 million, -$90.9 million, and -$84.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.